1. Home
  2. SIG vs ACAD Comparison

SIG vs ACAD Comparison

Compare SIG & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Signet Jewelers Limited

SIG

Signet Jewelers Limited

HOLD

Current Price

$90.31

Market Cap

3.4B

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$25.54

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SIG
ACAD
Founded
1950
1993
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Consumer Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.8B
IPO Year
1997
2000

Fundamental Metrics

Financial Performance
Metric
SIG
ACAD
Price
$90.31
$25.54
Analyst Decision
Buy
Buy
Analyst Count
7
22
Target Price
$111.14
$30.55
AVG Volume (30 Days)
790.2K
1.8M
Earning Date
06-02-2026
05-06-2026
Dividend Yield
1.65%
N/A
EPS Growth
974.07
69.12
EPS
0.78
0.02
Revenue
$6,247,100,000.00
$726,437,000.00
Revenue This Year
$1.39
$18.80
Revenue Next Year
$1.71
$11.70
P/E Ratio
$114.63
$1,282.50
Revenue Growth
N/A
40.45
52 Week Low
$71.62
$19.69
52 Week High
$110.20
$28.35

Technical Indicators

Market Signals
Indicator
SIG
ACAD
Relative Strength Index (RSI) 61.58 61.21
Support Level $88.69 $25.40
Resistance Level $93.42 $27.79
Average True Range (ATR) 3.07 0.80
MACD 0.65 -0.09
Stochastic Oscillator 82.13 35.24

Price Performance

Historical Comparison
SIG
ACAD

About SIG Signet Jewelers Limited

Signet Jewelers Ltd is a retailer of diamond jewelry. Its merchandise mix includes bridal, fashion, watches, and others. The bridal category includes engagement, wedding, and anniversary purchases. Its segments are the North America segment, the International segment, and the Other segment. The North America segment contributes to the majority of the revenue. The North America segment generates revenue from Mall and Outlet. Geographically, it operates in the USA, Canada, the UK, and Ireland, with the maximum revenue from the USA.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: